Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

John L. Black; Mark R. Litzow; William J. Hogan; Dennis J. O'Kane; Denise L. Walker; Timothy G. Lesnick; Walter K. Kremers; Rajeswari Avula; Rhett P. Ketterling

doi:10.1016/j.leukres.2011.06.020

Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

John L. Black, Mark R. Litzow, William J. Hogan, Dennis J. O'Kane, Denise L. Walker, Timothy G. Lesnick, Walter K. Kremers, Rajeswari Avula, Rhett P. Ketterling

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

CYP2B6, CYP2C19, ABCC4, and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment. 110 BMT patients who received high dose CPA treatment were genotyped for variants in these genes and the results were correlated with toxicity and relapse. CYP2B6 genotype significantly influenced overall toxicity suggesting active CYP2B6 alleles led to higher rates of overall toxicity. The p.R487C deficiency allele was significantly associated with a lower rate of overall toxicity and a higher rate of relapse. SOD2 rs4880 V16A polymorphism was associated with significantly less CPA-related overall toxicity and significantly lower relapse rates by Kaplan-Meier analysis although the SOD2 finding regarding relapse was not significant when evaluated by the cumulative incidence function.

Original language	English (US)
Pages (from-to)	59-66
Number of pages	8
Journal	Leukemia Research
Volume	36
Issue number	1
DOIs	https://doi.org/10.1016/j.leukres.2011.06.020
State	Published - Jan 2012

Keywords

ABCC4
Blood or marrow transplantation
CYP2B6
CYP2C19
Cyclophosphamide
SOD2

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2011.06.020

Cite this

@article{8bbc55cd1abf42a7b068e43f10297277,

title = "Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients",

abstract = "CYP2B6, CYP2C19, ABCC4, and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment. 110 BMT patients who received high dose CPA treatment were genotyped for variants in these genes and the results were correlated with toxicity and relapse. CYP2B6 genotype significantly influenced overall toxicity suggesting active CYP2B6 alleles led to higher rates of overall toxicity. The p.R487C deficiency allele was significantly associated with a lower rate of overall toxicity and a higher rate of relapse. SOD2 rs4880 V16A polymorphism was associated with significantly less CPA-related overall toxicity and significantly lower relapse rates by Kaplan-Meier analysis although the SOD2 finding regarding relapse was not significant when evaluated by the cumulative incidence function.",

keywords = "ABCC4, Blood or marrow transplantation, CYP2B6, CYP2C19, Cyclophosphamide, SOD2",

author = "Black, {John L.} and Litzow, {Mark R.} and Hogan, {William J.} and O'Kane, {Dennis J.} and Walker, {Denise L.} and Lesnick, {Timothy G.} and Kremers, {Walter K.} and Rajeswari Avula and Ketterling, {Rhett P.}",

note = "Funding Information: Funding source . There are no external sources of support in the form of grants and/or equipment or drugs to declare. This research was funded by the Mayo Clinic Department of Laboratory Medicine and Pathology . ",

year = "2012",

month = jan,

doi = "10.1016/j.leukres.2011.06.020",

language = "English (US)",

volume = "36",

pages = "59--66",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "1",

}

TY - JOUR

T1 - Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

AU - Black, John L.

AU - Litzow, Mark R.

AU - Hogan, William J.

AU - O'Kane, Dennis J.

AU - Walker, Denise L.

AU - Lesnick, Timothy G.

AU - Kremers, Walter K.

AU - Avula, Rajeswari

AU - Ketterling, Rhett P.

N1 - Funding Information: Funding source . There are no external sources of support in the form of grants and/or equipment or drugs to declare. This research was funded by the Mayo Clinic Department of Laboratory Medicine and Pathology .

PY - 2012/1

Y1 - 2012/1

N2 - CYP2B6, CYP2C19, ABCC4, and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment. 110 BMT patients who received high dose CPA treatment were genotyped for variants in these genes and the results were correlated with toxicity and relapse. CYP2B6 genotype significantly influenced overall toxicity suggesting active CYP2B6 alleles led to higher rates of overall toxicity. The p.R487C deficiency allele was significantly associated with a lower rate of overall toxicity and a higher rate of relapse. SOD2 rs4880 V16A polymorphism was associated with significantly less CPA-related overall toxicity and significantly lower relapse rates by Kaplan-Meier analysis although the SOD2 finding regarding relapse was not significant when evaluated by the cumulative incidence function.

AB - CYP2B6, CYP2C19, ABCC4, and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment. 110 BMT patients who received high dose CPA treatment were genotyped for variants in these genes and the results were correlated with toxicity and relapse. CYP2B6 genotype significantly influenced overall toxicity suggesting active CYP2B6 alleles led to higher rates of overall toxicity. The p.R487C deficiency allele was significantly associated with a lower rate of overall toxicity and a higher rate of relapse. SOD2 rs4880 V16A polymorphism was associated with significantly less CPA-related overall toxicity and significantly lower relapse rates by Kaplan-Meier analysis although the SOD2 finding regarding relapse was not significant when evaluated by the cumulative incidence function.

KW - ABCC4

KW - Blood or marrow transplantation

KW - CYP2B6

KW - CYP2C19

KW - Cyclophosphamide

KW - SOD2

UR - http://www.scopus.com/inward/record.url?scp=83555173440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555173440&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.06.020

DO - 10.1016/j.leukres.2011.06.020

M3 - Article

C2 - 21741706

AN - SCOPUS:83555173440

SN - 0145-2126

VL - 36

SP - 59

EP - 66

JO - Leukemia Research

JF - Leukemia Research

IS - 1

ER -

Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this